acute anterior wall ST-elevation myocardial infarction
Conditions
Interventions
Experimental group:Sacubitril/Valsartan(50mg/100mg/200mg bid)
Control groupEnalapril:Enalapril(2.5mg/5mg/10mg bid)
Sponsors
Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) >=18 years of age; (2) Had typical pain and Diagnosed as acute anterior STEMI according to electrocardiogram, high-sensitivity troponin, and coronary angiography; (3) Systolic blood pressure >=100mmHg without symptoms of dizziness during the last 12 hours prior to randomization; (4) Provide informed written consent.
Exclusion criteria
Exclusion criteria: (1) Previous history of myocardial infarction or chronic heart failure; (2) Previous PCI, coronary artery bypass graft (CABG), implantation of other heart assist devices or heart transplantation; (3) Estimated glomerular filtration rate 5.2 mmol /l at randomization; (4) Known hepatic impairment or history of cirrhosis; (5) Previous use of Sacubitril/Valsartan; (6) History of hypersensitivity or contraindications to the study drugs including ACEI, ARB, Sacubitril/Valsartan; (7) Life expectancy is less than 1 year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP;left ventricular ejection fraction (LVEF);left ventricular end-diastolic volumes (LVEDV);left ventricular end-systolic volumes (LVESV); | — |
Secondary
| Measure | Time frame |
|---|---|
| the composite of death, reinfarction, outpatient heart failure or heart failure hospitalization, arrhythmia, and stroke; | — |
Countries
China
Contacts
Public ContactXinghua Jiang
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed